Brenipatide for IBS-C

(RENEW-IBS-C Trial)

This trial tests a new treatment called brenipatide to evaluate its effectiveness and safety for individuals with Irritable Bowel Syndrome-Constipation (IBS-C). Participants will receive either brenipatide or a placebo via a small injection under the skin. The trial aims to assess the treatment's impact on symptoms such as infrequent bowel movements and abdominal pain. Individuals who regularly experience constipation and abdominal pain, particularly with hard or lumpy bowel movements, may be suitable candidates. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that brenipatide is usually well-tolerated by people with Irritable Bowel Syndrome with Constipation (IBS-C). Previous studies identified diarrhea as the most common side effect. Other side effects were rarely reported, suggesting they might be less common or less serious. This medication remains under investigation, making ongoing trials like this one crucial. They help identify any new side effects and confirm the treatment's safety.¹²³⁴⁵

Brenipatide for IBS-C is unique because it introduces a new approach with its active ingredient, LY3537031, which is administered subcutaneously. Unlike traditional IBS-C treatments that often focus on altering gut motility or increasing fluid secretion in the intestines, Brenipatide targets specific pathways differently. Researchers are excited about its potential to provide relief with fewer side effects and more convenient dosing compared to oral medications, which are the standard treatments. This could mean a more effective and patient-friendly option for managing IBS-C symptoms.

Research has shown that brenipatide might help ease symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). Early results indicate that patients experienced less abdominal pain and improved bowel movements. One study revealed that participants had a noticeable decrease in symptoms compared to those who took a placebo. This trial will compare brenipatide, administered subcutaneously, with a placebo to further evaluate its effectiveness and safety in managing IBS-C symptoms. However, more research is needed to confirm these findings and ensure its overall safety and effectiveness.¹²³⁴⁶